Page 2 of Novo Nordisk

Knock-offs of weight loss drug Ozempic to be banned in Australia

The change will be effective from October 1, giving patients time to source a regulated drug.

May 22, 2024 12:18 IST

Novo Nordisk's oral diabetes drug reduces heart-related risks by 14 percent

Weight lost through Wegovy can be sustained for up to four years, claims Novo Nordisk

Patients in the trial lost an average of nearly 10 percent of their total body weight after 65 weeks on…

May 14, 2024 15:15 IST

China develops first biosimilar of globally popular weight loss drug Ozempic; Application submitted for approval

The application for approval by Jiuyuan Gene Engineering comes amid surging demand for semaglutide that far outpaces supply globally.

April 3, 2024 15:59 IST

Ozempic not linked to suicidal thoughts, FDA report finds

European drug regulators last year announced an investigation after receiving reports of suicidal thoughts from patients taking GLP-1 drugs, including…

January 12, 2024 16:42 IST

Ozempic, USFDA, weight loss, Novo Nordisk, Eli Lilly, healthcare news, pharma news,

Ozempic knock-offs contain an unsafe substance banned by the FDA

The World Anti-Doping Agency has also banned the substance, which it says hasn’t been sufficiently studied.

December 1, 2023 08:00 IST

Ozempic, Wegovy, Novo Nordisk, healthcare news, pharma news,

Novo drugs Ozempic and Wegovy are shaking up stock markets again

As investors bet that this new class of weight-loss drugs will improve the overall health of millions of Americans, US…

October 12, 2023 16:21 IST

GlobalData, Rare Diseases, China market, healthcare news, pharma news,

UK looks to expand obesity-drug access with pilot program

Obesity costs the UK government £6.5 billion a year as one of the leading causes of severe health conditions such…

June 7, 2023 14:26 IST

New weight-loss drug found to be effective in pill form, Wegovy maker says

Novo stock rose 2.7% in Copenhagen on Monday, but its American depositary receipts declined in the US after the Pfizer…

May 23, 2023 12:05 IST

Obesity, Obesity drugs, semaglutide, cancer, cancer treatment, cancer research, healthcare news, pharma news,

This obesity drug also has cancer-killing properties; here’s how

People with obesity are more prone to developing disorders like type 2 diabetes, cardiovascular disease, and many types of cancer.

May 15, 2023 12:24 IST

Novo Nordisk, United Diabetes Forum and Harley Owners Group ride to raise awareness about obesity as a chronic disease

Obesity has far-ranging effects on one’s health and can lead to conditions such as high blood pressure, type 2 diabetes,…

April 25, 2023 12:45 IST

Ozempic, Ozempic weight loss, Oscars 2023, Jimmy Kimmel, novo nordisk, healthcare news,

All you need to know about weight loss drug ‘Ozempic’ that Jimmy Kimmel joked about during Oscars 2023

Weight Loss Drug, Ozempic: Reportedly, in people with heart problems, it can cause damage to the retina of the eye…

March 14, 2023 17:10 IST

Novo Nordisk, Novo Nordisk India, Insulin, diabetes, healthcare news,

FE Exclusive | There is still a lot of untapped opportunities in India’s diabetes market: John Dawber, Global Business Head, Novo Nordisk

John Dawber told Financial Express.com that other than focusing on insulin they will continue to work on innovative solutions for…

February 16, 2023 22:30 IST

Novo Nordisk, Novo Nordisk India, Healthcare News, Pharma news,

Pharma major Novo Nordisk completes 100 years; Hopes to advance further in diabetic care in coming years

On this occasion, the company launched a digital employee community outreach portal aimed at encouraging employees to volunteer for community…

February 16, 2023 15:53 IST

Diabetes, Obesity, non communicable diseases, Novo Nordisk, Novo Nordisk, health news, pharma news,

FE Exclusive | Therapies like once-a-week insulin, obesity-specific treatments to be launched in India soon: Vikrant Shrotriya, MD, Novo Nordisk India

Recently, global pharma major, Novo Nordisk, launched a campaign highlighting the relationship between diabetes and obesity.

December 7, 2022 14:15 IST

Novo nordisk, Eli Lilly, Type 2 diabetes market, health news, pharma news,

Novo Nordisk likely to maintain lead against competitor Eli Lilly in global type 2 diabetes market: GlobalData

Additionally, the launch of Rybelsus (oral semaglutide), which delivered similar efficacy to Ozempic for T2D, has significantly driven the sales…

November 11, 2022 11:29 IST

Non-communicable diseases, World Health Organization, Heart attacks, diabetes, cancer, health news, NCDs, healthcare news,

Novo Nordisk and Roche partner together to enhance access to care for children with Type 1 diabetes in India

This partnership is part of NNEF’s Changing Diabetes in Children (CDiC) programme which is a public-private partnership that provides “comprehensive…

Updated: August 4, 2022 16:57 IST

Novoeight, used in treatment of haemophilia A, now available in India

The active ingredient in NovoEight is turoctocog alfa, a B-domain truncated recombinant antihemophilic factor which is produced by third generation…

May 2, 2016 15:59 IST

Novo Nordisk names Sachin Tendulkar as brand ambassador of ‘Changing Diabetes’

The company has initiated the Changing Diabetes in Children, a programme designed to improve access to diabetes care for children…

January 6, 2016 09:43 IST

Related News

Radhakishan Damani's high-yield 'cash cows' trading near 52-week lows. (Image source: Canva)

Zero debt, high ROCE, solid dividends: 2 gems in Radhakishan Damani’s portfolio

2025 MAMA Awards: When and where to watch, full lineup, hosts, nominees and more

2025 MAMA Awards winners Day 1: Hearts2Hearts, Cortis crowned Best New Artists – Live

Jefferies top 11 Indian banks with up to 33% upside potential

Jefferies top 11 banking stocks with up to 33% upside potential

Aadhaar Card Update: Simple step-by-step guide to change your address online without hassle

Aadhaar Card Update: How to change address in Aadhaar Card online in simple steps

RBI slaps Rs 91 lakh penalty on HDFC Bank for regulatory lapses

Business44 min ago

The Reserve Bank of India has fined HDFC Bank Rs 91 lakh for violating banking regulations and failing to comply with KYC requirements. The penalty was imposed due to discrepancies in loan categorization, outsourcing of KYC compliance, and non-permissible business activity. However, the RBI clarified that it does not question the validity of the bank’s transactions or agreements.

View all shorts